KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Restructuring Costs: 2016-2024

Historic Restructuring Costs for Travere Therapeutics (TVTX) over the last 5 years, with Dec 2024 value amounting to $2.4 million.

  • Travere Therapeutics' Restructuring Costs fell 87.69% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 86.99%. This contributed to the annual value of $2.4 million for FY2024, which is 78.60% down from last year.
  • As of FY2024, Travere Therapeutics' Restructuring Costs stood at $2.4 million, which was down 78.60% from $11.4 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Restructuring Costs ranged from a high of $11.4 million in FY2023 and a low of $2.4 million during FY2024.
  • In the last 2 years, Travere Therapeutics' Restructuring Costs had a median value of $6.9 million in 2023 and averaged $6.9 million.
  • Data for Travere Therapeutics' Restructuring Costs shows a maximum YoY plummeted of 78.60% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Travere Therapeutics' Restructuring Costs stood at $11.4 million in 2023, then crashed by 78.60% to $2.4 million in 2024.